{"id":"etavopivat-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL4650332","moleculeType":"Small molecule","molecularWeight":"457.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etavopivat is a PKC activator that promotes the expression of fetal hemoglobin in erythrocytes. By increasing HbF levels, the drug reduces polymerization of sickle hemoglobin and improves red blood cell survival, thereby decreasing vaso-occlusive crises and hemolytic anemia in patients with sickle cell disease.","oneSentence":"Etavopivat activates the protein kinase PKC (protein kinase C) to increase fetal hemoglobin (HbF) production, thereby reducing sickling and hemolysis in red blood cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:39.783Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sickle cell disease"}]},"trialDetails":[{"nctId":"NCT06198712","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease","status":"RECRUITING","sponsor":"Forma Therapeutics, Inc.","startDate":"2023-01-12","conditions":"Sickle Cell Disease","enrollment":50},{"nctId":"NCT06581627","phase":"PHASE1","title":"A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-08-26","conditions":"Healthy Volunteers, Sickle Cell Disease, Thalassemia","enrollment":24},{"nctId":"NCT04987489","phase":"PHASE2","title":"A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease","status":"COMPLETED","sponsor":"Forma Therapeutics, Inc.","startDate":"2022-03-28","conditions":"Sickle Cell Disease, Thalassemia","enrollment":53},{"nctId":"NCT04624659","phase":"PHASE3","title":"A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Forma Therapeutics, Inc.","startDate":"2021-01-29","conditions":"Sickle Cell Disease","enrollment":450},{"nctId":"NCT05953584","phase":"PHASE2","title":"A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke","status":"RECRUITING","sponsor":"Forma Therapeutics, Inc.","startDate":"2023-06-20","conditions":"Sickle Cell Disease","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FT-4202"],"phase":"phase_3","status":"active","brandName":"Etavopivat tablets","genericName":"Etavopivat tablets","companyName":"Forma Therapeutics, Inc.","companyId":"forma-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etavopivat activates the protein kinase PKC (protein kinase C) to increase fetal hemoglobin (HbF) production, thereby reducing sickling and hemolysis in red blood cells. Used for Sickle cell disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}